Radical prostatectomy
Long‐term oncological outcome from a community hospital

References

• Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, Wolff JM, et al. EAU guidelines on prostate cancer. Eur Urol 2001; 40: 97–101.
   PubMed Web of Science ®Google Scholar
• Young HH. Radical perineal prostatectomy. Johns Hopkins Hosp Bull 1905; 16: 315–21.
   Google Scholar
• Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into aetiology and prevention. J Urol 1982; 128: 492–7.
   PubMed Web of Science ®Google Scholar
• Holmberg L, Bill-Axelsson A, Helgesen F, Salo J, Folmerz P. Häggman M, et al. A randomized trial com-paring radical pro statectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781–9.
   Google Scholar
• Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prosta-tectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555–65.
   Google Scholar
• Catalona WJ, Smith DJ. Five-year tumor recurrence rates after anatomic radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837–42.
   PubMed Web of Science ®Google Scholar
• Hull GW, Rabbani F, Abbas F, Wheeler TM, Kaftan MV, Scardino PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002; 167: 528–34.
   PubMed Web of Science ®Google Scholar
• Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum PSA after radical prostatectomy. J Urol 1994; 152: 1821–5.
   PubMed Web of Science ®Google Scholar
• Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850–7.
   PubMed Web of Science ®Google Scholar
• Begg CB, Riedel ER, Bach PB, Kaftan MV, Schrag D, Warren JL, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002; 346: 1138–44.
   PubMed Web of Science ®Google Scholar
• Sandblom G, Dufmats M, Nordenskj old K, Varenhorst E. Prostate carcinoma trends in three counties in Sweden 1987-1996: result from a population-based national cancer register. Cancer 2000; 88: 1445–53.
   PubMed Web of Science ®Google Scholar
• Andersson J, Ekman P. Egevad L, Hellström M. Rela-tively high risk of treatment failure after pro statectomy: tumour grade, histopathological stage and preoperative serum PSA level are key prognosticators. Scand J Urol Nephrol 2001; 35: 453–58.
   Google Scholar
• Van Poppel H, Collette L, Kirkali Z, Brausi M, Hoekstra W, Newling DW, et al. Quality control of radical prostatectomy: a feasibility study. Eur J Cancer 2001; 37: 884–91.
   PubMed Web of Science ®Google Scholar
• Weckermann D, Wawroschek F, Hamm M, Haude K, Harzmann R. Biochemical course after radical retropubic prostatectomy: preliminary results. Eur Urol 2001; 39: 418–24.
   Google Scholar
• Ravichandran S, Dasgupta P, Booth CM. Radical pro statectomy in Britain and Ireland at the millennium. BJU Int 2002; 90: 422–3.
   Google Scholar
• Amling CL, Bergstrahl EJ, Blute ML, Slezak IM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146–51.
   Google Scholar
• Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002; 90: 561–6.
   PubMed Web of Science ®Google Scholar
• Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000; 164: 1465–72.
   Google Scholar
• Kupelian P. Katcher J, Levin H, Zippe C, Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles and radical prostatec-tomy alone for clinically localized prostate cancer. Urology 1996; 48: 249–60.
   Google Scholar
• Egawa S, Suyama K, Arai Y, Tsukayama C, Matsumoto K, Kuwao S, et al. Treatment outcome by risk group after radical prostatectomy in Japanese men. Int J Urol 2001; 8: 295–300.
   PubMed Web of Science ®Google Scholar
• Graefen M, Augustin H, Karakiewicz PI, Hammerer PC, Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555�65.
   Google Scholar
• Haese A, Palisaar J, et al. Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of Partin Tables. Eur Urol 2003; 43: 6-11. Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003; 169: 157–63.
   Google Scholar
• Salomon L, Levrel 0, de la Taille A, Hoznek A, Chopin D, Abbou CC. Seminal vesicle invasion after radical prostatectomy: study of risk factors for progression. Prog Urol 2002; 12: 621–7.
   Google Scholar
• Vanasupa BP, Paquette EL, Wu H, Sun L, McLeod DG, Moul JD. The role of radical prostatectomy in patients with pretreatment prostate-specific antigen or =40 ng/ ml. Urol Oncol 2002; 7: 167–72.
   PubMedGoogle Scholar
• Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Bio-chemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 1999; 54: 884–90.
   PubMed Web of Science ®Google Scholar